Aldehyde dehydrogenase 2 in the spotlight: the link between mitochondria and neurodegeneration by Deza Ponzio, Romina et al.
Accepted Manuscript
Title: Aldehyde Dehydrogenase 2 in the spotlight: the link
between mitochondria and neurodegeneration
Authors: Romina Deza-Ponzio, Macarena Lorena Herrera,
Marı´a Jose´ Bellini, Miriam Beatriz Virgolini, Claudia Beatriz
Heren˜u´
PII: S0161-813X(18)30210-9
DOI: https://doi.org/10.1016/j.neuro.2018.06.005
Reference: NEUTOX 2346
To appear in: NEUTOX
Received date: 30-11-2017
Revised date: 8-5-2018
Accepted date: 11-6-2018
Please cite this article as: Deza-Ponzio R, Herrera ML, Bellini MJ, Virgolini
MB, Heren˜u´ CB, Aldehyde Dehydrogenase 2 in the spotlight: the link
between mitochondria and neurodegeneration, Neurotoxicology (2018),
https://doi.org/10.1016/j.neuro.2018.06.005
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
1 
 
Aldehyde Dehydrogenase 2 in the spotlight: the link between 
mitochondria and neurodegeneration 
 
Romina Deza-Ponzioa*, Macarena Lorena Herreraa,b*, María José Bellinib, 
Miriam Beatriz Virgolinia and Claudia Beatriz Hereñúa 
 
a Universidad Nacional de Córdoba, Facultad de Ciencias Químicas, Departamento de 
Farmacología. Córdoba, Argentina. Instituto de Farmacología Experimental Córdoba 
(IFEC-CONICET). 
b Universidad Nacional de La Plata, Facultad de Ciencias Médicas, Buenos Aires, 
Argentina. Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP-CONICET). 
*Romina Deza-Ponzio and Macarena Lorena Herrera contributed equally to this work. 
Corresponding author: Claudia Beatriz Hereñú 
e-mail address: cherenu@fcq.unc.edu.ar 
Phone 54-351-6340035 
Universidad Nacional de Córdoba, Facultad de Ciencias Químicas, Departamento de 
Farmacología. Córdoba, Argentina. Instituto de Farmacología Experimental Córdoba 
(IFEC-CONICET). Haya de la Torre S/N, esquina Medina Allende. Edificio Nuevo de 
Ciencias I. Ciudad Universitaria. Córdoba, Argentina. 
 
Highlights  
 
 Neurodegenerative diseases are threatening conditions that affect life-quality and 
life-span of the affected patients.  
 ALDH2 is a critical enzyme involved in neurotoxic mechanisms of PD and AD  
 4-HNE which is considered one of the fundamental signaling molecules in the 
pathogenesis of AD and its detoxification depend on ALDH2 activity. 
 ALDH2 activation is proposed as a therapeutic approach for PD, since the enzyme 
plays a crucial role in mitochondrial normal function maintenance that protects 
against neurotoxicity. 
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Abstract: Growing body of evidence suggests that mitochondrial dysfunctions and 
resultant oxidative stress are likely responsible for many neurodegenerative diseases, 
including Alzheimer´s disease (AD) and Parkinson´s disease (PD). Aldehyde 
dehydrogenase (ALDH) superfamily plays a crucial role in several biological processes 
including development and detoxification pathways in the organism. In particular, 
ALDH2 is crucial in the oxidative metabolism of toxic aldehydes in the brain, such as 
catecholaminergic metabolites (DOPAL and DOPEGAL) and the principal product of 
lipid peroxidation process 4-HNE. This review aims to deepen the current knowledge 
regarding to ALDH2 function and its relation with brain-damaging processes that 
increase the risk to develop neurodegenerative disorders. We focused on relevant 
literature of what is currently known at molecular and cellular levels in experimental 
models of these pathologies. The understanding of ALDH2 contributions could be a 
potential target in new therapeutic approaches for PD and AD due to its crucial role in 
mitochondrial normal function maintenance that protects against neurotoxicity. 
 
Keywords: Aldehyde dehydrogenase 2; mitochondrial dysfunction; Alzheimer´s Disease; 
Parkinson´s Disease; oxidative stress 
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dihydroxyphenylacetic acid; DOPAL, 3,4-dihydroxyphenylacetaldehyde; DOPEGAL, 
3,4-dihydroxyphenylglycolaldehyde; EPI, epinephrine; ER, endopolasmicreticulum; 
GWAS, genome-wideassociationstudies; HVA, homovanilicacid; MAO –B, 
monoaminoxidasetype; MDA, malondialdehyde; NAD, nicotine; NE, norepinephrine; 
OB, olfactorybulb; OE, olfactoryepithelium; PD, Parkinson´sDisease; PT, 
permeabilitytransition; ROS, reactive oxygenspecies; RAS, reactive aldehydespecies; 
SN, substantianigra; UV, ultraviolet light 
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Introduction 
Ample evidence suggests that mitochondrial dysfunctions are likely responsible for many 
neurodegenerative diseases, especially Alzheimer´s disease (AD) and Parkinson´s disease 
(PD). The variety of symptoms expressed in these neuropathologies may obey to the 
increase in cell death processes as consequence of early several mitochondrial disorders 
such as a deficient production of adenosine triphosphate (ATP), an increase in the release 
of proapoptotic factors and reactive oxygen species (ROS) generation, which increase 
oxidative stress susceptibility (Bhat et al., 2015). One of the consequences of this 
excessive oxidative stress status is the production of reactive and toxic aldehydes by lipid 
peroxidation from the membrane-rich mitochondria (Chen et al., 2016). Aldehydes have 
a reactive and electrophilic nature and commonly form adducts with macromolecules, but 
is also ubiquitous in the cell microenvironment, acquiring a toxic connotation. These toxic 
aldehydes are generated by the endogenous metabolism of neurotransmitters, amino 
acids, and lipids (Marchitti et al., 2007). Among them, lipid peroxidation-derived α, β-
unsaturated aldehydes such as 4-hydroxynonenal (4-HNE), malondialdehyde (MDA), 
acrolein, acetaldehyde, 3,4-dihydroxyphenylacetaldehyde (DOPAL, MAO product of 
dopamine) and 3,4-dihydroxyphenylglycoaldehyde (DOPEGAL, MAO product of 
norepinephrine) (Grünblatt & Riederer, 2014). A constant exposure to both, biogenic and 
xenogenic aldehydes contributes to the total aldehydic load in the neurons which, 
combined with mitochondrial dysfunction can lead to the neurological diseases 
previously mentioned. In this context, aldehyde dehydrogenase 2 (ALDH2), one of the 
most efficient human cell´s enzymes in metabolizing biogenic aldehydes, plays a crucial 
role in maintaining a proper metabolism by detoxifying cells from these aldehydic 
substrates (Chen et al., 2014). However, reactive aldehydes accumulation may inhibit 
ALDH2 and trigger mitochondrial dysfunction leading to a higher aldehyde-induced 
damage in several brain areas (Goldstein et al., 2013). 
1.1 Search Strategy and Selection Criteria 
Authors searched for peer-reviewed articles in PubMed database, Google scholar search 
platform, and Elsevier DataSearch. We considered articles including the most recent and 
remarkable studies in the field. The search terms were: "aldehyde dehydrogenase 2", 
"mitochondrial dysfunctions", "oxidative stress", "neurodegenerative diseases", 
"Parkinson´s disease", "Alzheimer´s disease", "genetics", "proteins", "cellular lines", 
"animal models". Additional articles were identified by searching the reference lists of 
identified reviews that provided insightful or comprehensive overviews on relevant 
aspects of the importance of detoxification in neurodegenerative diseases. 
 
 
1. Aldehyde dehydrogenase 2 in health and disease 
 
Aldehyde dehydrogenase (ALDH) superfamily is constituted by 9 families with 19 
isozymes known for playing a crucial role in several biological processes through 
development and senescence as well as detoxification pathways in the organism. They 
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are expressed in several subcellular compartments including the mitochondria, 
endoplasmic reticulum (ER), nucleus and cytosol in different tissues, such as gastric 
mucosa, heart, lungs, liver, retina, and brain (Alnouti et al., 2008). Among their functions, 
they catalyze NAD(P)+-dependent and irreversible oxidation of biogenic and exogenous 
aldehydes, to their corresponding carboxylic acids, some of them essential products for 
numerous cellular processes (Vasiliou et al., 2004). Additionally, ALDHs exert non-
enzymatic functions, acting as binding proteins for various compounds as hormones and 
cholesterol. Furthermore, they may have important antioxidant roles in NAD(P)H 
production, UV light absorption and the scavenging of hydroxyl radicals (Marchitti et al., 
2008).  
 
Both, ALDH1A1 and ALDH2 are involved in ethanol-derived acetaldehyde (ACD) 
oxidation to acetic acid, sharing a 68% amino acid similarity despite cytosolic ALDH1A1 
having less affinity for ACD (Km 50-180 µM) than mitochondrial ALDH2 (Km < 1 µM) 
(Marchitti et al., 2008). In particular, ALDH2 is highly expressed in several tissues 
including heart, liver and brain (Alnouti et al, 2008). In addition to the dehydrogenase 
function, ALDH2 also exhibits esterase and relevant nitrate reductase activity for nitrate 
bioactivation, including nitroglycerin formation (Marchitti et al., 2008; Vasiliou et al., 
2013). The ALDH2 substitution of Glu487 for Lys487, (ALDH2*2) is the most common 
and best studied single point mutation in humans that encodes an inactive mitochondrial 
isozyme and it is carried by nearly 50% of Asiatic population (Zhang et al., 2015). This 
mutation results in a deficient NAD(P) binding site with affected kinetic properties of the 
enzyme (Koppaka et al., 2012; Larson et al., 2007).  
 
Moreover, ALDH1A1 and ALDH2 are also involved in the metabolism of 
catecholamines, such as dopamine (DA), norepinephrine (NE) and epinephrine (EPI), due 
to their expression in relevant brain regions. (Grünblatt & Riederer, 2014). Importantly, 
the cytosolic enzyme ALDH1A1 is strongly expressed in DA neurons of the ventral 
tegmental area (VTA) and substantia nigra (SN) playing a role in the maintenance of 
dopaminergic system integrity (Anderson et al., 2011). It has been thus pointed-out that 
ALDH1A1 and ALDH2 may metabolize DA-derived aldehydes in a complementary 
fashion, although other isoenzymes participation cannot be ruled-out (Marchitti et al, 
2007). 
Thus, in brain DA is oxidized to 3,4-dihydroxyphenylacetaldehyde (DOPAL) in close 
apposition to the outer membrane of the mitochondria due to the MAO localization in this 
organelle (Doorn et al., 2014). DOPAL is mainly degraded by ALDH to 3, 4-
dihydroxyphenylacetic acid (DOPAC) and finally converted by the enzyme catechol O-
methyltransferase (COMT) to homovanillic acid (HVA), the final product of DA 
metabolism (see Marchitti et al., 2007 for an extensive review of DA metabolites). In 
contrast, NE and EPI are first converted into DOPEGAL whose metabolism occurs 
primarily by a reductive pathway that involves aldehyde reductases enzymes (AR). It is 
known that both, DOPAL and DOPEGAL are highly reactive and toxic bioproducts 
capable to pass through the cell membrane and condense with numerous molecules 
inducing damage into the brain integrity and disrupting homeostasis, affecting thereby 
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neurotransmission-related events. It has been shown that DOPAL induces cell death in 
vitro (Burke et al., 2004) and in vivo (Burke et al., 2003), produces aggregation and adduct 
formation of alpha-synuclein (Burke et al., 2008; Follmer et al, 2015), disrupts 
neurotrophic cell signaling (Kang et al., 2017) and promotes ROS formation and 
enhanced cross-linking of protein, probably as a result of its oxidation to a semiquinone 
radical and to an ortho-quinone (Anderson et al., 2011). Moreover, DOPAL disrupts the 
mitochondrial functionality by inducing the permeability transition (PT) of isolated 
mitochondria from neuronally differentiated PC12 cells, a cytotoxic effect that was 
prevented by PT inhibitors (Kristal et al., 2001). 
Some authors have ascribed a preponderant role to ALDH2 in DOPAL-detoxification 
pathways in the dopaminergic circuit (Doorn et al., 2014; Florang et al., 2007). The ROS 
and toxic aldehydes generated by DA metabolism lead to increased levels of cellular 
oxidative stress, lysosomal as well as mitochondrial damage, NAD + depletion and DNA-
directed alterations all of which are the main cause of neuronal injury and dysfunction 
which in turn induce apoptosis in the affected neurons (Burbulla et al., 2017; Adams et 
al., 2001).  
In this regard, it is known that oxidative stress triggers lipid peroxidation increasing 4-
HNE levels with resulting mitochondrial dysfunction due to a decrease in the membrane 
potential of this organelle. Importantly, 4-HNE, a derivative aldehyde generated by the 
reaction of superoxide with unsaturated fatty acid is oxidized with high efficacy by 
ALDH2 (Breitzig et al., 2016).  
In this framework, mutations and polymorphisms of ALDH2 which lead to an impaired 
enzymatic function are the basis of several pathological conditions due to the 
accumulation of cytotoxic aldehydes, including 4-HNE, a toxic bioproduct associated to 
aging and neurodegenerative diseases (Chen et al., 2015; Wey et al., 2012). These 
pathologies are characterized by impairments of cell metabolism and regulatory processes 
including mitochondrial dysfunction, vesicular transport alterations, lipid peroxidation, 
protein cross-linking and oxidative stress. All these events may be the consequences of 
an excessive aldehyde accumulation as is proposed by the catecholaldehyde hypothesis 
of neurodegeneration (Panneton et al., 2010; Goldstein et al., 2013.; Casida et al., 2014). 
In the context of this hypothesis, the role of the enzyme ALDH2 in the most prevalent 
neurodegenerative disorders in humans, i.e. Alzheimer´s and Parkinson´s disease will be 
discussed in the following sections.    
 
2. Alzheimer’s Disease 
In 1906 Dr. Alois Alzheimer described the spectrum of a “presenile dementia” and 
observed two major pathological processes i.e. amyloid beta (Aβ) and Tau protein 
deposition that still remain as the main explanation of the pathogenesis of Alzheimer´s 
Disease (AD) (Sery et al., 2013). Nowadays, AD is the most common neurodegenerative 
disease worldwide, where aging constituted the major risk factor.  It is characterized by 
synapse loss (predominantly within the neocortex area) and by the presence of certain 
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distinctive lesions as a consequence of protein misfolding throughout the brain (Chang et 
al., 2014).  
As many neurological diseases, AD is linked to oxidative stress, which is considered the 
most common effector of the cascade of the degenerative events (Benedetti et al., 2014). 
Oxidative stress can be evidenced in the blood, cerebrospinal fluid (CSF), and brain of 
neurologic patients with probable AD diagnosis (Chang et al., 2014). The appearance of 
early oxidative stress markers in these patients and in animal models of AD before either 
cognitive dysfunction or Aβ plaques and intracellular neurofibrillary tangles become 
apparent, suggests that oxidative damage may be a primary event in AD pathogenesis 
(D´Souza et al., 2015). In this context, ROS play a key role in lipid peroxidation, resulting 
in the formation of many aldehydic products, like 4-HNE which is considered one of the 
fundamental signaling molecules in the pathogenesis of AD (Benedetti et al., 2014; 
Bradley et al., 2010; Butterfield et al., 2011). Like other aldehydes, 4-HNE detoxification 
depends on ALDH2 activity provided that its inhibition increases the vulnerability to 4-
HNE induced damage (Bradley et al., 2010). A more profound knowledge of these 
mechanisms will provide new insights regarding therapeutic approaches that may prevent 
or reverse AD progression. 
High ALDH2 protein levels are found in the central nervous system and peripheral 
tissues. Its activity is more intensively studied in reference to the mechanisms involved 
in ALDH2 alterations in AD brains (Michel et al., 2010). As we previously described, 
ALDH2 is a known target for oxidation under conditions of oxidative stress (Ohsawa et 
al., 2003). Several studies reported its association as a neuroprotective enzyme against 
oxidative stress and neurodegeneration and its deficiency as a risk factor for elevated 
oxidative stress and subsequent AD development (Singh et al., 2010; Ohta et al., 2004). 
Poon et al. described molecular events associated with the aging olfactory system and its 
correlation with AD. They report a comparative proteomic analysis of age-related 
differences in expressed proteins of the olfactory epithelium (OE) and olfactory bulb 
(OB) of old (80-week old) and young (6-week old) mice. In these studies, they found that 
ALDH2 protein levels were down-regulated in the OE of old mice compared to young 
mice, which may result in an increased susceptibility to oxidative stress in the old mice’s 
OE (Poon et al., 2005). Previous reports found increased ALDH2 levels in the cerebral 
cortex of AD patients, where the immunoreactivity was prominent in senile plaques in 
the temporal cortex (Picklo et al., 2001). Michel et al. found an increase of ALDH2 
activity in the putamen of these patients, but no differences were detected in the frontal 
cortex (Michel et al., 2010).   
3.1 Molecular Alterations 
Genetic aberrations account for only a small proportion of AD cases (<5%) and only a 
few of them are related to mitochondrial dysfunction and a correlation of oxidative stress 
to aldehyde detoxification. Several reports of genetic modifications, such as genome-wide 
association studies (GWAS) and single genetic association studies, have reported gene 
variation on ALDH2 in East Asian patients (Hao et al., 2011). In this respect, Ma et al. 
(2016) investigated the association between ADH1B rs1229984 and ALDH2 rs671 
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polymorphisms and the development of Alzheimer's disease in a Chinese population. 
Regarding ALDH2 rs671, the AA genotype was correlated with an increased risk of 
Alzheimer's disease as compared to the GG genotype and associated with Alzheimer's in 
both dominant and recessive models. In addition, the Glu504Lys single nucleotide 
polymorphism (SNP) of the ALDH2 gene, which affects ALDH2 enzymatic activity 
leading to accumulation of toxic aldehydes such as ACD, is a potential candidate genetic 
risk factor for a variety of chronic diseases such as cardiovascular disease, cancer, and 
late-onset Alzheimer’s disease (Zhao & Wang., 2015; Li et al., 2009), interacting 
synergistically with the presence of the apolipoprotein E allele 4 (APOE ε4) (Kamino et 
al., 2000; Ohsawa et al., 2003; Ohta et al., 2004; Kim et al., 2004; Wang et al., 2008). 
On the other hand, the association between the mutant allele of mitochondrial aldehyde 
dehydrogenase (ALDH2*2) and Alzheimer's disease (AD) has been controversial during 
the last decades. Meta-analysis studies and the database www.alzgene.org showed that 
the ALDH2 genotype was not found to be associated with increased AD risk. Among 
these studies, Shin et al. investigated the longitudinal association between ALDH2*2 and 
AD incidence, reporting no significant associations among the ALDH2*2 and any 
cognitive outcomes (incidence of dementia or cognitive decline) (Shin et al., 2005). 
Similarly, in a Mongolian population, the ALDH2 gene may not represent a risk factor in 
the development of AD provided that its correlation with APOE ε4 displays no disparity 
(Zhou et al., 2010). Furthermore, a case-control study of the Japanese population 
associated or not with high alcohol consumption was not able to find any significant 
association of ALDH2 polymorphisms and dopamine β hydroxylase genes with AD risk 
(Komatsu et al., 2014).  
3.2 In vitro and In vivo models  
Cellular models are an appropriate approach to reproduce and understand the functional 
effects of specific genetic polymorphisms. For example, Ohsawa et al. demonstrated that 
the presence of the ALDH2*2 gene in PC12 cells resulted in the suppression of 
mitochondrial but not cytosolic ALDH activity in these cells, which were highly 
vulnerable to exogenous 4-HNE (Ohsawa et al., 2003). Furthermore, the treatment of 
human endothelial cells with amyloid β peptides induced loss of mitochondrial membrane 
potential, increased cytochrome c release and ROS accumulation, events that were 
associated with 4-HNE accumulation and a 40% decrease in ALDH2 activity. A selective 
ALDH1A1 and ALDH2 activator, Alda-1 (Kotraiah et al., 2013) abolished this 4-HNE 
accumulation and may have reduced endothelial injuries, preserving the angiogenic 
potential of the endothelium, mainly in the amyloid angiopathy (Solito et al., 2013). 
Furthermore, in primary rat hippocampal neurons, the increased expression of ALDH2 
protected the neurons against 4-HNE-induced  neurite damage and resultant oxidative 
stress (Bai & Mei., 2011). 
On the other hand, the study of late-onset/age-related AD etiology has been hampered by 
a paucity of animal models. D´Souza et al., hypothesized that in mice lacking ALDH2 4-
HNE accumulates and causes the appearance of AD-like pathological changes including 
increases of amyloid-beta, p-tau, activated caspases and the decrease of synaptic proteins 
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in hippocampal slices and brain atrophy leading to cognitive dysfunction in behavioral 
tests, pathological manifestations that are rarely observed in current AD animal models 
(D´Souza et al., 2015). Nevertheless, Ohta and Ohsawa found similar results in mice of 
18-months-old knock-out for ALDH2 (Ohta and Ohsawa., 2006) while the correlation 
between cognitive impairment and degeneration was accelerated by APOE knock-out two 
years later (Ohsawa et al., 2008). 
These lines of evidence were taken into consideration to create a double-transgenic AD 
mouse model to explore the pathological and behavioral effects of oxidative stress 
(Kanamaru et al., 2015). In this opportunity, mice who express a mutant form of the 
human amyloid precursor protein (APP) were crossed with DAL mice expressing a 
dominant-negative mutant of mitochondrial ALDH2. They observed that the life-span of 
APP/DAL mice was significantly shorter than their control APP or DAL counterparts 
while this double-transgenic mouse also showed accelerated amyloid deposition, tau 
phosphorylation and gliosis (Kanamaru et al., 2015).  
3. Parkinson´s Disease 
Two hundred years have passed since James Parkinson published An Essay on the 
Shaking Palsy where he first described the neurological disorder that today bears his name 
(Przedborski., 2017). Parkinson´s disease (PD) has become the second most common 
neurodegenerative disorder after AD and its etiology remains unclear. It is characterized 
by the progressive loss of dopaminergic neurons in the susbtantia nigra pars compacta 
(SNpc) projecting to the putamen and caudate nucleus of the brain (Schapira et al., 2017). 
This dopaminergic deficiency within the basal ganglia leads to parkinsonian cardinal 
motor symptoms including rigidity, bradykinesia and tremor. However, PD is also 
associated with numerous non-motor symptoms (cognitive dysfunction, 
neuropsychological symptoms, sleeping disorders, etc.) with some preceding the motor 
dysfunction for more than a decade (Kalia et al., 2015).  
It is now known that PD involves multiple neuroanatomical structures with an etiology 
resulting from the interplay between genetics and environment, with more prevalent 
environmental origins. Treatments to relieve the symptoms aim to increase DA 
concentrations or to stimulate DA receptors. Among the multiple hypotheses for PD´s 
etiology, oxidative stress and aldehyde-related toxicity are major components in the 
pathophysiology of this disorder (Michel et al., 2014; Grünblatt & Riederer, 2014). The 
increased ROS production and resultant oxidative stress could lead to cell death and 
degeneration. These molecules stimulate the production of aldehydes which may be toxic 
if ALDH activity is reduced, particularly ALDH1A1 and ALDH2, as we mentioned, are 
crucial in the deposition of neurotoxic metabolites, such as DOPAL and DOPEGAL. 
Concerning this aspect, when injected into ventrotegmental area (Burke et al., 2003) or 
into the substantia nigra (SN) (Panneton et al., 2010) DOPAL was neurotoxic to the DA 
neurons supporting the role of this catecholamine-derived aldehyde in PD etiology.  
Furthermore, 4-HNE and malondialdehyde (MDA), have been found to be significantly 
increased in post-mortem SN of PD patients. Interestingly, although 4-HNE is a substrate 
of ALDH2, the enzyme can also be inactivated by 4-HNE by covalently adducting to the 
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Cys in the catalytic site of the enzyme, which in turn increases DOPAL levels, thereby 
interlinking the oxidative stress and the catechol aldehyde hypothesis (see Chen et al., 
2014 and Florang et al., 2007). 
Thus, the studies of genetic modifications in cellular and animal models are crucial to 
understanding the specific pathogenesis of PD and therefore important to identify 
potential targets and or therapeutic-related approaches intended to relive the severe 
symptoms that affect the life quality of these patients.  
 
4.1 Molecular Alterations 
Large genome-wide association studies (GWAS) have identified more than two dozen 
common genetic variants for PD, each with a relatively small effect size; in combination 
with rare Mendelian genes, genetics account for at most 10–20 % of PD (Ritz et al., 2016). 
Although there is no ALDH2 gene variation in the different databases determined as a 
risk factor for PD development, it was reported that an Asian specific single nucleotide 
polymorphism, rs671, causes reduced enzymatic activity. Thus, PD patients with reduced 
ALDH2 activity owing to this polymorphism are at risk for neuropsychological 
impairments (Yu et al., 2016). In addition, other ALDH2 polymorphisms (haplotype of 
rs737280, rs968529, rs16941667, rs16941669, rs9971942) have been reported and 
associated with the exacerbation of PD risk (Fitzmaurice et al., 2014). In a Chinese cohort, 
ALDH2 tag-single nucleotide polymorphisms, including rs4767944, rs441, and rs671, 
were extracted and analyzed, with the results suggesting an association between PD 
susceptibility and ALDH2 polymorphisms (Zhang et al., 2015). Nevertheless, in an 
analysis of genotype distributions in an Iranian PD patient population, no significant 
relationships were observed between rs4767944 polymorphism of the ALDH2 and PD 
(Madadi et al., 2016). Zhao et al. studied the role of ADH2 Arg47His and ALDH2 
Glu487Lys genetic polymorphisms in PD development in a Chinese population. The 
ALDH2 Glu487Lys polymorphism in the dominant, co-dominant or recessive models 
were found to be significantly associated with the elevated risk of PD (Zhao et al., 2015). 
Moreover, a differential expression in ALDH2 activity according to the brain regions 
analyzed was reported with an increased activity of this enzyme in the putamen of PD 
patients while no significant differences in the frontal cortex area were informed (Michel 
et al., 2014).  
4.2 In vitro and In vivo models 
PD is believed to be caused by genetic factors, environmental exposures and their 
interactions (Zhang et al., 2015; Fitzmaurice et al., 2014). Wey et al. hypothesized a 
decreased function of ALDH2 consequential to exposure to environmental toxins and its 
correlation with this neuropathology. To prove their hypothesis, they generated mice null 
for ALDH1A1 and ALDH2 and observed significant increases in biogenic aldehydes 
reported to be neurotoxic, including 4-HNE and DOPAL. Consequently, this knock-out 
animal model could be useful to understand impaired detoxification of biogenic 
aldehydes and its importance in the pathophysiology of PD (Wey et al., 2012). Moreover, 
the activation of ALDH2 could be a neurotherapeutic approach for PD, since it plays a 
AC
CE
PT
ED
 M
AN
US
CR
IPT
10 
 
crucial role in maintaining mitochondrial normal function to protect against 
neurotoxicity. Additionally, in some parkinsonism´s animal models, the intraperitoneal 
administration of Alda-1, a potent activator of ALDH2 reduced significantly cell death in 
dopaminergic neurons, induces a decrease in ROS accumulation, a reversal of 
mitochondrial membrane potential depolarization, and an inhibition of the activation of 
proteins related to the mitochondrial apoptotic pathway (Chiu et al., 2015). Alternatively, 
trapping agents such as hydralazine may prevent adduct formation (Burcham & Pike., 
2006) or prevent cognitive damage by the administration of deuterium-reinforced 
polyunsaturated fatty acids that would mitigate lipid peroxidation-induced oxidative 
damage (Elharram et al., 2017). 
4. Conclusion 
Evidence presented in this review provides new insights regarding the importance of 
ALDH2 and its relationship with the two most common neurodegenerative diseases. In 
the last decades and with the development of state-of-the-art technologies, novel 
neurochemical circuits have been described, a fact that contributed to clarifying the 
knowledge of the cellular and molecular mechanisms involved in neuropathology and 
neurodegeneration (Figure 1). Compelling reports have attributed to brain-generated 4-
HNE a key role in chronic neurodegenerative insults. Moreover, the main mitochondrial 
enzyme in charge of its detoxification, ALDH2 needs to be further studied taking as well 
into consideration the numerous polymorphisms present worldwide, particularly in the 
Asiatic population. Thus, to sum up, ALDH2 could be a potential target in new 
therapeutic approaches for PD and AD provided its crucial role in mitochondrial normal 
function maintenance that is required to protect against aldehyde-induced neurotoxicity. 
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Figure Legend 
 
Figure 1. Role of ALDH2 in the cellular events that determine the health vs disease 
status of the neuronal environment.  
Boldness and size typography denotes putative differences in expression and in/or 
functionality of the enzyme. 
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